- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | SL Science Holding Limited Non-GAAP EPS of $0.00, revenue of $1.38B | 1 | Seeking Alpha | ||
| SL SCIENCE Aktie jetzt für 0€ handeln | |||||
| Mo | SL Science Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | SL Science Holding Limited Reports First Half 2026 Financial Results | 1 | GlobeNewswire (USA) | ||
| 09.10. | SL Science Holding Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 24.09. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.09. | SL Science Holding Limited: SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing Gamma delta T Cells Target Chemotherapy-Resistant Glioblastoma | 4 | GlobeNewswire (USA) | ||
| 02.09. | SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company | 1 | GlobeNewswire (USA) | ||
| 27.08. | SL Science licensor files exosome drug master file with FDA | 3 | Investing.com | ||
| 27.08. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.08. | SL Science Holding Limited: SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform | 491 | GlobeNewswire (Europe) | TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular... ► Artikel lesen | |
| 17.07. | SL Science presents glioblastoma treatment data at WCP 2026 | 3 | Investing.com | ||
| 17.07. | SL Science präsentiert Daten zur Glioblastom-Behandlung auf Weltkongress | 1 | Investing.com Deutsch | ||
| 17.07. | SL Science Holding Limited: SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology | 1 | GlobeNewswire (USA) | ||
| 10.07. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.07. | SL Science seeks orphan drug status for brain cancer therapy | 4 | Investing.com | ||
| 10.07. | Hirntumortherapie: SL Science beantragt Orphan-Drug-Status | 3 | Investing.com Deutsch | ||
| 10.07. | SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma | 709 | GlobeNewswire (Europe) | Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Limited Reports Full Year 2025 Financial Results | 591 | GlobeNewswire (Europe) | Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 15.06. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 11 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,135 | 0,00 % | Bye, bye Börse: Delisting: DAX-Aktie Qiagen wird wohl bald verschwinden | © Foto: Andreas Arnold/dpaDer Private-Equity-Riese EQT will Qiagen übernehmen. Experten trauen dem Angebot den Durchbruch zu. Der Diagnostik-Konzern dürfte anschließend von der Börse genommen werden.... ► Artikel lesen | |
| PARABILIS MEDICINES | 26,550 | 0,00 % | Parabilis reports phase 1/2 data for desmoid tumor treatment | ||
| TECTONIC THERAPEUTIC | 20,340 | 0,00 % | Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients | APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)APEX Phase... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,645 | -17,77 % | Rapport Therapeutics slides after pricing securities offerings | ||
| MODERNA | 192,54 | +3,88 % | Moderna-Aktie über 240 US$ - wie viel geht noch? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und stieg gestern um +6,69% auf 242,08 US$. Damit erreicht der Biotech-Titel den höchsten Stand seit Anfang 2022 und überwindet eine wichtige... ► Artikel lesen | |
| VERADERMICS | 140,39 | -0,21 % | Biotech Stocks At 52-Week Highs - Pacira BioSciences +44% On Acquisition News; Veradermics +14%, Haemonetics +17%, Concentra Group, HealthStream | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on October 8, 2026, driven by catalysts such as reports of an upcoming acquisition or upcoming financial reports.Pacira... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 18,150 | 0,00 % | Arcus Biosciences prices $250M public offering at $17.50 per share | ||
| PRAXIS PRECISION MEDICINES | 272,29 | +1,76 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| EVOTEC | 2,924 | +1,67 % | Evotec-Aktie mit +15% - steht die Trendwende jetzt an? | Die Evotec-Aktie meldet sich mit einem Wochenplus von +6,08% zurück und notiert bei 2,72 €. Von einer nachhaltigen Erholung kann dennoch keine Rede sein: Seit dem Rekordhoch hat der Biotech-Titel fast... ► Artikel lesen | |
| PRENETICS GLOBAL | 18,440 | 0,00 % | Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million | Total revenue of $46.5 million, up ~288% YoY (~3.9x); within the Company's guidance of $46-48 millionIM8 revenue of $45.0 million, up ~359% YoY (~4.6x); within the Company's guidance of $44-46 million... ► Artikel lesen | |
| OBSIDIAN THERAPEUTICS | 14,250 | 0,00 % | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 88,90 | -0,15 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| BIONTECH | 78,55 | +0,51 % | BioNTech und Gilead kooperieren bei Phase-3-Studie gegen Brustkrebs | BioNTech hat mit dem US-Pharmakonzern Gilead Sciences eine klinische Studienkooperation zur Behandlung von dreifach-negativem Brustkrebs vereinbart. Im Mittelpunkt steht die Kombination des Wirkstoffkandidaten... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,645 | -1,06 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,340 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SL SCIENCE HOLDING LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,190 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SL SCIENCE HOLDING LIMITED finden Sie auf Wallstreet Online.